iming is suspect; on day after achn sends what i think is a pretty clear signal that 3422 results are positive, bmy cancels their program; also, achn execs have a bmy background
it's hard to imagine that there's not a bmy/achn connection now
Prior to joining Achillion, Dr. Deshpande was Associate Director of Lead Discovery and Early Discovery Chemistry at the Pharmaceutical Research Institute at Bristol-Myers Squibb from 1991 to 2001, where he managed the identification of new clinical candidates to treat
Not going to sell for 17.00 per share
They are nuts not to lock in a huge profit.
Its part of take over deal
They still hold 10 million plus shares
Getting Bought sooner rather than later
There are two things..the phase 2 trial news,and possible take over news.It got a little quiet as of late.I think sooner rather than later we hear something
Thanks.I am hopeful for a buy out in the very near future.I can't imagine a 250 billion dollar market and this company with a golden opportunity for a bigger co not getting snapped up..